{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -0.23808934, "regularMarketPrice": 2.095, "exchange": "LSE", "shortName": "ORYZON GENOMICS SA ORYZON GENOM", "longName": "Oryzon Genomics S.A.", "messageBoardId": "finmb_2985449", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "marketState": "POSTPOST", "esgPopulated": false, "sharesOutstanding": 33492800, "bookValue": 1.313, "fiftyDayAverage": 2.2319458, "fiftyDayAverageChange": -0.13694572, "fiftyDayAverageChangePercent": -0.061357103, "twoHundredDayAverage": 2.3787959, "twoHundredDayAverageChange": -0.28379583, "twoHundredDayAverageChangePercent": -0.11930231, "marketCap": 765456, "priceToBook": 1.5955827, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1481788800000, "priceHint": 4, "regularMarketChange": -0.004999876, "regularMarketTime": 1683788428, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 486, "regularMarketPreviousClose": 2.1, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 968, "averageDailyVolume10Day": 184, "fiftyTwoWeekLowChange": 2.095, "fiftyTwoWeekRange": "0.0 - 2.975", "fiftyTwoWeekHighChange": -0.8799999, "fiftyTwoWeekHighChangePercent": -0.2957983, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 2.975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.088, "symbol": "0RDB.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Sant Ferran 74", "city": "Cornell\u00e0 de Llobregat", "zip": "08940", "country": "Spain", "phone": "34 93 515 13 13", "fax": "34 93 377 40 28", "website": "https://www.oryzon.com", "industry": "", "sector": "", "longBusinessSummary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornell\u00e0 de Llobregat, Spain.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carlos Manuel Buesa  Arjol", "title": "Co-Founder, Chairman, CEO & Pres", "fiscalYear": 2015, "totalPay": {"raw": 58000, "fmt": "58k", "longFmt": "58,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Enric Rello Condomines", "title": "Director of Operations, COO & CFO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jordi Xaus Pey", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Xavier Perpinya Ribera", "title": "Head of Internal Audit & Compliance", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Emili Torrell Cortada", "title": "Chief Bus. Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Neus Virgili Bernado", "title": "Chief Intellectual Property Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael Thomas Ropacki Ph.D.", "title": "Chief Medical Officer of CNS", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sonia Paloma Gutierrez Bezon", "title": "Chief of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Saikat  Nandi", "title": "Global Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ana  Limon", "title": "Sr. VP of Clinical Devel. & Global Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1451520000, "maxAge": 86400}}], "error": null}}